Lenacapavir is a twice-yearly injection that can prevent HIV infections. New licensing deals with Gilead and Indian manufacturers mean it will be available in 120 low- and middle-income countries at about US$40 a year.
The Gates Foundation will help Hetero with funding and volume guarantees and says it invested more than US$80 million to speed production. Dr. Reddy’s will receive help from the Clinton Health Access Initiative, Unitaid and Wits RHI to supply generics from 2027 at the same price. Campaigners warn some middle-income countries are excluded and that money is also needed for awareness, training and supply.
Difficult words
- drug — A substance used for medical treatment.
- injection — A shot given using a needle.
- countries — Nations or areas with their own governments.
- access — The ability to use or reach something.
- funding — Money provided for a specific purpose.
- healthcare — Services related to health and medical care.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is lenacapavir considered a major step in fighting HIV?
- How do you think funding can improve healthcare services?
- What might happen if middle-income countries are excluded from access?
Related articles
Cholera spreads where water and health systems fail
Cholera spread widely in 2024, with 560,823 reported cases and 6,028 deaths. Conflict, climate shocks and damaged water and health services drove outbreaks, while vaccines and better water and sanitation are key to preventing deaths.
Study warns of heavier rain and hotter nights in Tanzania
New research warns parts of Tanzania will see more extreme rainfall and rising temperatures. Experts say farmers, health and cities will be affected and call for stronger national policies, preparedness and community climate finance.